SOUTH SAN FRANCISCO, Calif. — Titan Pharmaceuticals Monday announced that it has executed a product purchase and supply agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan’s novel maintenance treatment for Opioid Use Disorder (OUD) in eligible patients.

Titan expects the majority of Probuphine sales in the United States to be through the specialty pharmacy distribution model, where a specialty pharmacy carries inventory, directly handles the subsequent patients’ insurance billing and payment processes, and ships to the healthcare provider as prescribed. This system is designed to facilitate patient access to treatment by streamlining the product ordering and fulfillment process for healthcare providers and their staff.  In February 2019, Titan announced a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime. Titan’s strategic expansion of its network to include Accredo, one of the largest U.S. specialty pharmacies, is a key component of its focused commercialization strategy for Probuphine.

“We are proud to partner with Accredo as we expand the specialty pharmacy distribution network for Probuphine in the United States,” said Titan’s chief commercial officer, Dane Hallberg. “Accredo is among the top specialty pharmacy networks in the U.S. with excellent relationships with third-party payors that should enhance the ability of OUD patients to gain access to long-term maintenance treatment with Probuphine.”

Express Script’s Advanced Opioid Management program received the Pharmacy Benefit Management Institute’s excellence award in the opioid management strategy category in March 2018.